Clinical Diagnostics Market Size, Share, Growth and Forecast, 2025-2035

Clinical diagnostics shift to molecular and bedside tests

The global clinical diagnostics market was valued at USD 92.37 billion in 2025 and is projected to increase from USD 96.79 billion in 2026 to USD 147.31 billion by 2035, registering a CAGR of 4.78% during 2026–2035. Demand comes from routine blood chemistry, immunoassay and hematology panels ordered in hospitals every day, plus infectious disease, cancer and genetic tests that guide treatment choices. Aging populations and higher rates of diabetes, heart disease and cancer raise test volumes in every region. North America held the largest regional share, 40.0% in 2025, on high test use per person and large reference laboratory networks. Asia Pacific is the fastest-growing region at 6.03% a year, as China and India expand hospital laboratories and insurance coverage. The main commercial change is a wave of consolidation that is reshaping ownership of major laboratory and molecular testing brands.

Which tests, analyzers and buyers fall inside the scope?

The market counts manufacturer revenue from in vitro test instruments, reagent kits and consumables used to analyze blood, urine, tissue and other samples for patient care. It covers clinical chemistry, immunoassay, molecular, hematology, coagulation, microbiology and urinalysis platforms. Buyers include hospital laboratories, independent reference laboratories, physician offices, point-of-care sites and consumers using home tests.

The scope excludes laboratory service fees charged to patients and payers, diagnostic imaging equipment and research-use-only products sold to academic or drug discovery customers. Software sold separately from analyzers and blood glucose meters used for daily self-monitoring are also excluded from the market value.

Reagent kits and immunoassays hold the largest value

Why do kits hold the largest share?

Based on product, the market is categorized into instruments, kits and consumables. Kits led with a 58.0% share of 2025 value, because analyzers are often placed under reagent rental contracts and earn recurring revenue from every test run. Kits grow fastest at 4.97% a year through 2035, as molecular panels, cancer profiling tests and home kits add new reagent demand while instrument replacement cycles stay long.

How fast is testing moving outside the central laboratory?

Based on test type, the market is categorized into lab based, point of care and home based tests. Lab Based testing led with a 74.0% share of 2025 value, because high-throughput hospital and reference laboratories process most routine panels. Home Based Test kits grow fastest at 7.23% a year, as consumers buy self-tests for infections, fertility and chronic disease, and as telehealth providers order sample collection at home.

Which technology leads, and which grows fastest?

Based on technology, the market is categorized into clinical chemistry, immunoassay and immunochemistry, molecular diagnostics, hematology, coagulation and hemostasis, microbiology, urinalysis and others. Immunoassay & Immunochemistry led with a 27.0% share of 2025 value, because immunoassay analyzers run cardiac, thyroid, fertility and infectious disease markers on one platform. Molecular Diagnostics grows fastest at 6.16% a year, as PCR panels and sequencing move into routine care.

Where is test demand concentrated by disease area?

Based on application, the market is categorized into infectious diseases, oncology, genetic testing, cardiovascular disease and others. Infectious Diseases led with a 32.0% share of 2025 value, because respiratory, sexually transmitted, bloodstream and tuberculosis tests are ordered in high volumes worldwide. Genetic Testing grows fastest at 6.81% a year, as hereditary risk panels, newborn screening and carrier testing reach more patients through lower sequencing costs.

Chronic disease, infection control and cancer screening

How does the infectious disease burden sustain test volumes?

Infectious diseases remain the largest single source of diagnostic demand, especially where detection gaps are wide. In 2023, the WHO reported that about 8.2 million people were newly diagnosed with tuberculosis, up from 7.5 million in 2022, while an estimated 10.8 million fell ill. The gap of about 2.7 million undiagnosed or unreported cases shows the room for wider molecular testing. As a result, national programs keep expanding rapid tests in primary care, which supports volume growth in Asia Pacific and Africa.

Why do aging and chronic disease raise routine testing?

Older adults and patients with diabetes, kidney disease and heart disease need regular blood tests to manage treatment. Routine chemistry and immunoassay panels, such as HbA1c, lipids, troponin and kidney function, account for a large share of daily laboratory work. Because these conditions are chronic, testing repeats several times a year for each patient. This steady demand keeps hospital laboratories investing in high-throughput analyzers and reagent contracts across all regions. In turn, large hospital laboratories process thousands of routine samples each day, which sustains reagent orders.

Download Free Sample

How does precision oncology expand molecular testing?

Targeted cancer drugs need biomarker tests to select patients, which links new therapies to new diagnostic revenue. In August 2024, Illumina announced FDA approval of TruSight Oncology Comprehensive, a pan-cancer profiling test with companion claims for NTRK fusion solid tumors and RET fusion lung cancer. In November 2025, Abbott and Exact Sciences announced a merger agreement at USD 105.00 per share in cash, adding cancer screening and precision oncology tests. These moves show how oncology testing lifts the value earned per test.

Why are governments funding decentralized testing?

Health systems want faster results closer to patients, which favors point-of-care testing in clinics, emergency rooms and community sites. On Dec. 5, 2024, the WHO announced its first prequalification of a tuberculosis test, Cepheid's Xpert MTB/RIF Ultra molecular assay. Prequalification lets donors and national programs buy approved tests with confidence. In turn, near-patient molecular platforms gain access to large public tenders in low- and middle-income countries.

Consolidation, decentralized testing and genomic profiling

Why is consolidation reshaping supplier ranks?

Large deals are changing who owns key testing franchises, as companies focus portfolios on higher-growth assays. In February 2026, Waters completed its combination with BD's Biosciences and Diagnostic Solutions businesses and formed a new advanced diagnostics division covering microbiology, molecular and point-of-care testing. Waters shareholders own about 60.8% of the combined company and BD shareholders about 39.2%. In October 2025, Hologic agreed to be acquired by Blackstone and TPG for up to USD 79 per share. This shift concentrates scale and investment in fewer, larger owners.

How is laboratory automation changing the workflow?

Laboratories are rising to staff shortages by linking analyzers, sample handlers and middleware into automated lines. Automation lets one technologist oversee chemistry, immunoassay and hematology analyzers at once, which raises throughput per employee. Suppliers sell these systems under long contracts that bundle reagents and service. As a result, large hospital networks and reference laboratories consolidate testing in fewer, more automated sites and smaller hospitals send specialty work to these hubs for faster turnaround.

Download Free Sample

Where is the opening in home and self-testing?

Home testing offers an opening for suppliers that can deliver accurate results without a laboratory visit. Consumers now buy self-tests for respiratory infections, fertility, colorectal cancer screening and sexually transmitted infections through pharmacies and online stores. Telehealth providers also send home collection kits for blood and urine panels. This channel grows fastest among test types, although regulators require clear labeling and accuracy data before approval. Because results reach patients directly, suppliers also invest in apps that explain results and link users to follow-up care.

Can genomic testing reach routine care?

Falling sequencing costs create an opportunity to move genetic testing from specialist centers into routine care. Hereditary cancer panels, carrier screening, pharmacogenomic tests and newborn sequencing are gaining coverage in the U.S. and parts of Europe. Illumina, QIAGEN and Agilent supply instruments, library preparation kits and analysis software for these workflows. If payers widen coverage, genetic testing could add strong reagent demand through 2035. However, laboratories also need trained genetic counselors and data storage, which raises the cost of each new program.

Pricing pressure, regulatory change and staff shortages

How does reimbursement pressure limit test prices?

Payers cut or freeze fees for routine tests, which squeezes laboratory budgets and supplier prices. In the U.S., public fee schedules for common chemistry and hematology tests have faced repeated reviews, while China uses volume-based procurement for some reagents. These policies push laboratories to demand lower reagent prices from suppliers. As a result, value growth for mature tests trails volume growth, and suppliers shift investment toward higher-value molecular and oncology assays.

Why does regulatory change raise compliance costs?

Diagnostic regulation in Europe and the U.S. has changed sharply since 2024, which adds cost and uncertainty for manufacturers. Regulation (EU) 2024/1860 extended IVDR transition periods to Dec. 31, 2027, for class D devices and to the end of 2028 and 2029 for lower classes. In the U.S., a court vacated the FDA rule on laboratory-developed tests in March 2025. These shifts force suppliers to maintain parallel compliance plans across markets.

What do staff shortages mean for laboratories?

Many hospital laboratories struggle to recruit and keep trained technologists, which limits how many tests they can run. Vacancies lengthen turnaround times and push laboratories to outsource specialty tests to reference networks. Smaller sites may delay adding new assays because they lack staff to validate them. This constraint favors suppliers of automated systems but slows adoption of complex manual tests. In turn, training programs and remote support from suppliers have become part of many analyzer contracts.

Why does post-pandemic normalization weigh on growth?

Respiratory testing surged during the COVID-19 pandemic and then fell sharply, which left some suppliers with excess capacity. Companies wrote down inventories and restructured molecular businesses as demand returned to seasonal patterns. Although multiplex respiratory panels keep some of the gains, infectious disease value now grows more slowly than oncology and genetic testing. This normalization holds the overall market growth rate near 4.78% a year, well below the surge seen in 2020 and 2021.

U.S. laboratories lead while Asia Pacific gains fastest

North America leads on test use and molecular adoption

North America held a 40.0% share of 2025 value and grows at 4.33% a year through 2035. The U.S. has large hospital laboratories and national reference networks that process high volumes of chemistry, immunoassay and molecular tests. The FDA rule on laboratory-developed tests was formally vacated in September 2025, according to a notice reported by AABB, which preserves flexibility for laboratories. However, fee pressure still limits value growth for routine chemistry and hematology tests.

Europe adapts to the IVDR transition

Europe held a 27.0% share of 2025 value and grows at 4.03% a year, the slowest pace among the five regions. Germany, France, Italy and the U.K. account for most demand, with public hospital laboratories buying through tenders. The IVDR transition requires new conformity assessments for many tests, which has led some suppliers to retire low-volume assays. However, Siemens Healthineers, bioMerieux, QIAGEN and Randox keep strong positions in their home markets.

Download Free Sample

Asia Pacific grows on laboratory expansion

Asia Pacific held a 24.0% share of 2025 value and is the fastest-growing region at 6.03% a year. China and India are adding hospital beds, laboratories and insurance coverage, which raises test volumes per person. Japan supports high-value testing, and Sysmex leads in hematology from its home base. Domestic suppliers in China compete on price in chemistry and immunoassay, while multinational firms focus on high-end platforms.

Latin America builds private laboratory networks

Latin America held a 5.0% share of 2025 value and grows at 5.33% a year through 2035. Brazil and Mexico lead the region, where private laboratory chains run large automated centers. Public systems buy tests through tenders and often face budget limits and currency swings. As a result, growth depends on private chains that adopt molecular and immunoassay panels.

Middle East and Africa widen access to testing

The Middle East & Africa held a 4.0% share of 2025 value and grows at 5.53% a year. Gulf states invest in new hospitals and centralized laboratories with modern automation. In sub-Saharan Africa, donor-funded programs for tuberculosis, HIV and malaria drive much of the demand for molecular and rapid tests. Of an estimated 400,000 people who developed multidrug-resistant TB in 2023, only 44% were diagnosed and treated, which shows the need for wider testing. WHO prequalification helps these programs buy approved tests at scale.

Download Free Sample

Major deals and regulatory changes since 2024

Automation, multiplex PCR and next-generation sequencing

• Total laboratory automation links sample handling, analyzers and storage so fewer staff can run more tests each day.
• Multiplex PCR panels detect many respiratory, gastrointestinal or bloodstream pathogens from one sample in about an hour.
• Next-generation sequencing profiles hundreds of cancer genes or a full exome in one run to guide therapy choices.
• High-sensitivity immunoassays measure cardiac troponin and other markers at very low levels for faster emergency decisions.
• Connected point-of-care analyzers send results directly to electronic records from clinics, pharmacies and emergency rooms.

Installed analyzers lock in recurring reagent revenue

Competition centers on installed analyzers, because each system locks in years of reagent sales. Abbott, Siemens Healthineers and Danaher, through Beckman Coulter and Cepheid, lead in chemistry, immunoassay and molecular platforms. Sysmex is the leading hematology specialist, while bioMerieux and BD, now part of Waters in diagnostics, are strong in microbiology. Hologic focuses on women's health and molecular testing, QIAGEN on sample preparation and syndromic panels, and Illumina and Agilent on sequencing and genomic workflows. Bio-Rad supplies quality controls and specialty assays, and Randox Laboratories offers broad chemistry and multiplex arrays. Recent deals show that scale in reagents and service now matters more than single assays, and suppliers compete on menu breadth, automation and connectivity.

Companies profiled and their roles in this market

Molecular and oncology testing carry the growth premium

Credence Research's view is that molecular, oncology and genetic testing will carry the growth premium in clinical diagnostics through 2035. Routine chemistry and immunoassay still supply most of the value, but fee pressure keeps their growth below the market average. Suppliers with large installed bases, broad test menus and automation earn steady reagent revenue and can cross-sell new assays. Recent deals show that owners are paying for scale in cancer screening and molecular testing, which suggests further consolidation as smaller firms seek partners.

How the 2025 baseline and forecast were built

The report uses 2025 as the base year and forecasts market value to 2035, with growth rates stated for 2026–2035. Market values come from the Credence Research market model, which combines test volumes by technology and region with average reagent and instrument prices. Splits by product, test type, technology, application and region are Credence Research estimates. Sources used include WHO disease statistics and prequalification notices, regulatory records from the U.S. and the EU, and company press releases and filings. No primary interviews or surveys were used to build the estimates in this report.

Testing moves closer to patients through 2035

By 2035, the market reaches USD 147.31 billion, with kits and consumables still providing most of the value. Molecular testing gains share as multiplex panels and sequencing move into routine care, and oncology becomes a larger part of laboratory work. Point-of-care and home testing grow faster than central laboratories as health systems push care closer to patients. Asia Pacific adds the most new test volume, led by China and India. Consolidation continues, and suppliers with automation and broad menus gain share.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.